Lucira Health (NASDAQ:LHDXQ – Get Rating) and MyMD Pharmaceuticals (NASDAQ:MYMD – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.
This is a summary of recent ratings for Lucira Health and MyMD Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
57.0% of Lucira Health shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 30.4% of Lucira Health shares are held by company insiders. Comparatively, 3.6% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Lucira Health has a beta of 3.24, meaning that its share price is 224% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500.
Earnings and Valuation
This table compares Lucira Health and MyMD Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Lucira Health||$93.06 million||0.05||-$64.83 million||($3.58)||-0.03|
|MyMD Pharmaceuticals||N/A||N/A||-$15.20 million||($0.36)||-6.28|
MyMD Pharmaceuticals has lower revenue, but higher earnings than Lucira Health. MyMD Pharmaceuticals is trading at a lower price-to-earnings ratio than Lucira Health, indicating that it is currently the more affordable of the two stocks.
Lucira Health beats MyMD Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
About Lucira Health
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
About MyMD Pharmaceuticals
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.